Cowen and Company’s Pulmonx LUNG Stock Holding History

Cowen and Company’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,700	Closed	-$2.51K	–	640
2022 Q4	$2.51K	Buy	+6,700	New	+$63.7K	﹤0.01%	549

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cowen and Company's LUNG Position: Q1 2023 in Review

Cowen and Company sold out of Pulmonx (LUNG) in Q1 2023, closing a stake of 5,126 shares — an estimated $43.2K sold.

Cowen and Company first reported a position in LUNG in Q4 2022 and held it in 1 quarter. The position peaked at $43.2K in Q4 2022. 102 funds tracked by Wall St. Rank hold LUNG as of Q1 2023.

Cowen and Company reported no remaining Pulmonx position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 5,126 Pulmonx shares in Q1 2023, an estimated $43.2K.
Cowen and Company first reported a position in Pulmonx in Q4 2022 and held it in 1 quarter.
Cowen and Company's Pulmonx position peaked at $43.2K in Q4 2022.
102 funds tracked by Wall St. Rank held Pulmonx as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.